United States — Food and Drug Administration & Novartis

United States — Food and Drug Administration: The FDA granted the approval, expanding Pluvicto's use to earlier-stage metastatic prostate cancer, a regulatory decision that broadens treatment options and sets a precedent for radioligand therapies.

Novartis: Novartis received FDA approval to expand Pluvicto's indication to mHSPC, nearly doubling the eligible patient population and reinforcing its leadership in radioligand therapy. This is expected to drive future revenue growth, though the stock dipped 1.45% on the announcement.

United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.

Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.

United States — Food and Drug Administration: The FDA granted accelerated approval for TRUTAKNA based on proteinuria reduction, with continued approval contingent on confirmatory data.

Novartis: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.

United States — Food and Drug Administration: The United States — Food and Drug Administration encourages the adoption of advanced manufacturing technologies and continuous production models, reinforcing the shift from reactive to proactive compliance strategies in the pharmaceutical industry.

Novartis: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.

United States — Food and Drug Administration: The FDA granted Fast Track designation to PentixaFor, facilitating its development and regulatory review.

Novartis: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.

United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.

Novartis: Competitor in acromegaly market.

United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.

Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.

Novartis: Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.